Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin Pamoate 3-Month vs 1-Month Formulation in Endometriosis
NCT03232281Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triptorelin pamoate in endometriosis (2 arms), sponsored by Ipsen. Primary endpoint: Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at 12 weeks. Started Jul 2017; status: completed.
02
Drugs
triptorelin pamoate
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03232281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232281.